Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ACETAMINOPHEN vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Management of moderate to moderately severe pain (FDA approved),Off-label: acute pain, postoperative pain
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release). Acetaminophen: 1.5-3 hours. Clinical context: Half-life may be prolonged in hepatic impairment, elderly, and renal failure.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Oxycodone is extensively metabolized in the liver via CYP3A4 (primarily) and CYP2D6 (minor) to noroxycodone, oxymorphone, and other metabolites. Acetaminophen is metabolized in the liver mainly via glucuronidation and sulfation with a minor CYP2E1 pathway producing toxic NAPQI.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Oxycodone: renal (primarily as noroxycodone, oxymorphone, and conjugated metabolites; <10% unchanged). Acetaminophen: renal (85-90% as sulfate and glucuronide conjugates; 2-4% unchanged; 8-10% as cysteine and mercapturate conjugates). Biliary/fecal excretion: minor (<5% for both).
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Oxycodone: 38-45% (primarily to albumin). Acetaminophen: 10-25% (minimal binding).
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Oxycodone: 2.6-3.0 L/kg (wide distribution into tissues). Acetaminophen: 0.9-1.0 L/kg (uniformly distributed in body fluids).
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Oral immediate-release: oxycodone 60-87%, acetaminophen 68-88%. Oral extended-release: oxycodone 60-87% (less variable). Rectal: variable (unspecified for this combination).
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: acetaminophen no change, oxycodone consider 75% of usual dose; Cr Cl 10-29 m L/min: acetaminophen extend interval to q6h, oxycodone consider 50% of usual dose; Cr Cl <10 m L/min: acetaminophen avoid or 650 mg q8h, oxycodone 50% of usual dose; hemodialysis: acetaminophen 650 mg q8h, oxycodone 25-50% of usual dose.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: oxycodone reduce dose by 50%, acetaminophen maximum 2000 mg/day; Child-Pugh C: oxycodone reduce dose by 75%, acetaminophen maximum 2000 mg/day; severe hepatic impairment: avoid acetaminophen component.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Children ≥6 months: 0.05-0.15 mg/kg oxycodone (based on oxycodone component) every 4-6 hours, maximum single dose 5 mg; acetaminophen 10-15 mg/kg/dose, maximum 75 mg/kg/day (up to 4000 mg/day). Weight-based oxycodone not to exceed adult dose.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Start at 50% of adult dose (oxycodone 2.5-5 mg every 6 hours), titrate cautiously; maximum acetaminophen 3000 mg/day due to decreased hepatic reserves; monitor for renal impairment and avoid if Cr Cl <30 m L/min.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; accidental ingestion may be fatal; risk of hepatotoxicity with acetaminophen overdose.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; hepatotoxicity (acetaminophen); severe hypotension; adrenal insufficiency; seizures; increased risk of overdose in patients with head injury or COPD.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Hypersensitivity to oxycodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; known or suspected gastrointestinal obstruction; severe hepatic impairment (acetaminophen).
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Avoid alcohol consumption; increases risk of hepatotoxicity from acetaminophen and potentiates CNS depression. Grapefruit juice may increase oxycodone absorption; avoid concurrent use. High-fat meals can delay oxycodone peak concentration, potentially reducing rapid pain relief. No specific restrictions with other foods.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
First trimester: Risk of neural tube defects not significantly increased with therapeutic use; opioid dependence may increase risk of congenital malformations (e.g., gastroschisis). Second/third trimester: Chronic use may cause fetal opioid dependence, leading to neonatal abstinence syndrome (NAS). Late third trimester: Risk of respiratory depression in neonate if used near delivery.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Excreted into breast milk in low concentrations. M/P ratio for oxycodone: 3.2:1; acetaminophen: approximately 1.0. Considered compatible with breastfeeding with caution; monitor infant for sedation and feeding difficulties. Avoid if maternal codeine use due to CYP2D6 ultrarapid metabolism concerns (though oxycodone less affected).
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
No standard dose adjustment required for maternal pharmacokinetic changes. Increased renal clearance in pregnancy may slightly reduce acetaminophen levels, but therapeutic effect maintained. Oxycodone metabolism via CYP3A4 and 2D6; pregnancy-induced enzyme changes may alter clearance, but clinical significance unclear. Use lowest effective dose, avoid NSAIDs if co-prescribed.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Maximum daily acetaminophen dose is 4000 mg from all sources; prescribed combination tablets contribute to this limit. Oxycodone immediate-release duration is 3-6 hours; avoid crushing extended-release formulations. Both components have abuse potential; screen for opioid use disorder. In renal impairment, adjust dosing interval for oxycodone; avoid in Cr Cl <30 m L/min. In hepatic impairment, the acetaminophen component may be hepatotoxic; avoid in severe disease. Coadministration with serotonergic agents may precipitate serotonin syndrome. Naloxone is the reversal agent for oxycodone; acetylcysteine for acetaminophen overdose.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take other products containing acetaminophen (e.g., Tylenol, cold medications) to avoid exceeding the maximum daily dose of 4000 mg.,Avoid alcohol while taking this medication; liver damage risk increases with alcohol use.,Do not crush, break, or chew tablets; swallow whole to avoid rapid release of oxycodone.,This medication can cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Store securely out of sight and reach of children; dispose of unused medication via a drug take-back program.,Take with food if nausea occurs; avoid high-fat meals as they may delay absorption.,Do not stop abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering schedule.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCODONE AND ACETAMINOPHEN vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE, answered by our medical review team.
OXYCODONE AND ACETAMINOPHEN is a Opioid Agonist that works by Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCODONE AND ACETAMINOPHEN and ACETAMINOPHEN AND HYDROCODONE BITARTRATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCODONE AND ACETAMINOPHEN is: Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.. The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining OXYCODONE AND ACETAMINOPHEN and ACETAMINOPHEN AND HYDROCODONE BITARTRATE. Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Oxycodone. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. OXYCODONE AND ACETAMINOPHEN is classified as Category D/X. First trimester: Risk of neural tube defects not significantly increased with therapeutic use; opioid dependence may increase risk of congenital malformations (e.g., gastroschisis). ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.